- Home
- VTYX vs PRQR Comparison
VTYX vs PRQR Comparison
Compare VTYX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- PRQR
- Stock Information
- Founded
- VTYX 2018
- PRQR 2012
- Country
- VTYX United States
- PRQR Netherlands
- Employees
- VTYX N/A
- PRQR N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- PRQR Health Care
- Exchange
- VTYX Nasdaq
- PRQR Nasdaq
- Market Cap
- VTYX 154.9M
- PRQR 163.3M
- IPO Year
- VTYX 2021
- PRQR 2014
- Fundamental
- Price
- VTYX $1.70
- PRQR $1.66
- Analyst Decision
- VTYX Buy
- PRQR Strong Buy
- Analyst Count
- VTYX 4
- PRQR 7
- Target Price
- VTYX $11.33
- PRQR $9.00
- AVG Volume (30 Days)
- VTYX 1.5M
- PRQR 470.6K
- Earning Date
- VTYX 05-08-2025
- PRQR 05-08-2025
- Dividend Yield
- VTYX N/A
- PRQR N/A
- EPS Growth
- VTYX N/A
- PRQR N/A
- EPS
- VTYX N/A
- PRQR N/A
- Revenue
- VTYX N/A
- PRQR $21,212,711.00
- Revenue This Year
- VTYX N/A
- PRQR $2.87
- Revenue Next Year
- VTYX N/A
- PRQR N/A
- P/E Ratio
- VTYX N/A
- PRQR N/A
- Revenue Growth
- VTYX N/A
- PRQR 85.91
- 52 Week Low
- VTYX $0.78
- PRQR $1.07
- 52 Week High
- VTYX $5.66
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- VTYX 61.97
- PRQR 52.16
- Support Level
- VTYX $1.68
- PRQR $1.66
- Resistance Level
- VTYX $1.85
- PRQR $1.83
- Average True Range (ATR)
- VTYX 0.15
- PRQR 0.10
- MACD
- VTYX 0.04
- PRQR -0.00
- Stochastic Oscillator
- VTYX 67.05
- PRQR 48.48
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.